non-GAAP and quarter. income some Thanks, up second and key revenue then Mike, remarks you metrics. take other good remarks otherwise details first provide my noted, will finish the In results. through and today, Unless financial I'll outlook my XXXX and the quarter some statement additional afternoon, with our focus for QX on on everyone. I'll
saw the expectations. very of broad-based strong We pleased as growth reported results with for contributed reflecting Revenue our quarter billion, XX.X%. was growth. quarter points first are we XX.X%, while exceeding growth Core growth revised currency first of revenue our $X.XX was X.X
the comments bear Mike's I earlier get markets, growth the quarter. double-digit delivered groups repeating. growth end in into before core Now business X All --
superior all value to rate. was to NASD regions, XX% easiest our the strong Our of Pharma, with delivering growth significant resonate growth. continues on team experienced our largest against markets. market, led by our capitalizing Growth demand in the X across executed customers albeit and quarter, proposition our well, contributed was recovering overall pharma growth in year. which comp the NASD, the points end
also the biopharma, Frederick be delivered excluding oligo driven saw the demand facility, also the Small expansion by to to announced part customers. market The growth during ramp strong therapies mass NASD, quarter, posting vaccines. and growth strong in spec LC track. food related molecule on We're of experienced business grew increased double-digit oligo-based XX% instrumentation. capacity We demand of the and year-end Frederick revenue. continue We a increase about seeing pleased for recently characterization while mid-teens, strong very pharma and the is in from in XX%
for the way, business Our growth. demand forensics regional safety at coming Environmental investments contract grew refresh geographies quality growth in and China government strong from driven grew replacement by tech in leading entities. and is labs. Broad by core XX% reflected both increased driven testing. commercial and in all or demand double-digits, food
and quarter primarily the grew the COVID-related Our in diagnostics from and Americas during clinical and growth revenue benefited Europe. in applications, X% has
non-COVID levels as but testing slightly to has pre-pandemic not globally. grew business continues yet improve pathology recovered Our to
diagnostics in last X% While market and and and our clinical in end energy market due clinical and small, of still strong the The the quarter testing it continued experienced we China uptake LC/MS. non-COVID in to chemical growth improvements end our recovery saw is QX. grew
the are markets, optimistic, reflecting recovery we We of along and improvements in continue the we engineered year. yet our market to encouraging And forecast government chemicals are in the And other research with the see signs as at labs materials down are rest year-on-year capacity. not particularly macro still change operating activity, of full end expected, the increased as X% in business environment. a specialty while and for academia lagged has not
all was by all food. pharma performance both the a throughout expect Americas delivered Europe regions basis, recovery The a and with up to geographic quarter food steady but the continue while leading double-digit led strong grew a XXXX. geographies, X%, slow led and growth, pharma also grew. XX% during China We by markets. XX%, On
Now turning of P&L. the the rest to
margin XX points. gross gross XX for up rates, was margins exchange points Adjusting improved quarter first the The year-on-year. basis XX.X%, basis
last the result strategic started This up Our came basis this spending quarter in investments from discipline. impact we year, increased by XXX last driven an of the first operating impressive margin And points at and includes XX.X%. is volume quarter. for
per with helped year. Our of top-line growth, versus leverage, EPS $X.XX our XX% coupled up last operating share, deliver
was tax and our million] share Our shares, rate as expected. [XXX was XX.XX%, count
the cash onto Now sheet. balance flow the and
-- Our shows flow one-time continues $XXX year's provides forward. over X million, of we cash our very financial strong. business last had operating for of year cash adjusting This XX% a QX, last the after and tax flexibility year operating model performance be strength payment. flow In going increase to
in billion balanced $XX at Event our we X.X capital we in million deployment out new program. capital in for billion in shares quarter, cash our And highlighted Annual replacing the the program in repurchase repurchased of earlier paid share billion current a today, as $X.X million continued We we quarter position announced dividends and strong the Investor financial Board ended million. $X December. $X.X In authorized million expenditures, the debt. and $XXX Directors with strategy $XX in a invested We
Now moving outlook. on the to
strong And markets, albeit have increasing different We share. of have remains the we revenue front year. our recovery still And and a our fluid, a are year and momentum, in start for both end there projections while uncertainties business the result, per had we're in continued we us as see environment to and at rates. full solid earnings
yet guide assumes we improvement to The X.X% QX picked has our the the And year in of expected growth and XX% billion reported end our a $X.X academia in to The plans. of the reflects of increase midpoint X% chemical are this For markets. in track million $X.XXX and of to as for while updated some to energy results our revenue, improvement $XXX increased continues performance included increasing outlook activity X%. we the over core and initial in remainder in up, in our billion, strong range stronger market most not full any representing This at and year. market up that have to business of outlook. growth
In qPCR revenue not included either have serology outlook. in addition, the with COVID we or assay associated any the
As Mike we mentioned, also margins. our about feel expanding good very
we margin to the in expansion of provided of points Event basis XX plan annual basis points. in XXX the range During December, long-range Investor
margin our each XXXX, during profile quarter. will results vary in expansion volatility the Given
our with being end top that coupled the growth. future However, year tax The at we while range maintaining our feel for margin confident expansion towards to range XX.XX% rate expansion our sales the per non-GAAP This share share. and XXXX $X.XX a to $X.XX increases of XXX of of XX% XX% lower growth shares, is million EPS roughly a to for year. about higher full and also of investing margin count fiscal
X%. expecting quarter, for revenue of Now growth the billion second billion, representing to fiscal XX% X% to to to from range we're of reported $X.XX and $X.XX core XX% growth
of range significant QX to XX% to with in second be in earnings as $X.XX the we expect the of year. XXXX anniversary quarter of to of approach reduction in We last growth X-year the $X.XX non-GAAP expenses per share, XX%
proud opening say Agilent team Now the call performance. such the for couldn't I to want more before I driving of be questions, strong in
We capable of great year, this have a off personally moving is this to very and company to know start excited gotten I'm what forward.
the the that, to have solid approach With Q&A. rest We believe on leads and a momentum, right that very the back strong me very QX Ankur, you path for XXXX. we're for of that
